LadRx Corp (LADXD)

[mlkrborn]

CytRx reports preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib was clinically active (CYTR) 0.88 +0.09 : Co announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer. Based on this indication of clinical activity and the low incidence of adverse events, additional patients enrolled in the ENABLE Phase 2 clinical trial will receive bafetinib as a single agent at a higher dose.